Clinical Study
Outpatient-Based Therapy of Oral Fludarabine and Subcutaneous Alemtuzumab for Asian Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
Figure 1
OFSA Treatment
schedule. CR: Complete remission, MRD: Minimal residual disease.